Johnson & Johnson $JNJ Stake Boosted by Auxano Advisors LLC

Auxano Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% in the 2nd quarter, Holdings Channel.com reports. The fund owned 15,635 shares of the company’s stock after buying an additional 630 shares during the quarter. Johnson & Johnson comprises about 0.6% of Auxano Advisors LLC’s holdings, making the stock its 28th biggest position. Auxano Advisors LLC’s holdings in Johnson & Johnson were worth $2,388,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. NorthStar Asset Management LLC NJ increased its position in Johnson & Johnson by 5.1% in the 2nd quarter. NorthStar Asset Management LLC NJ now owns 6,125 shares of the company’s stock worth $936,000 after purchasing an additional 296 shares during the last quarter. Prudential PLC increased its holdings in Johnson & Johnson by 52.3% in the second quarter. Prudential PLC now owns 402,943 shares of the company’s stock worth $61,550,000 after buying an additional 138,355 shares during the last quarter. Winnow Wealth LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $295,000. Ensign Peak Advisors Inc lifted its stake in Johnson & Johnson by 2.4% in the second quarter. Ensign Peak Advisors Inc now owns 2,535,992 shares of the company’s stock valued at $387,373,000 after acquiring an additional 59,609 shares during the last quarter. Finally, Empirical Finance LLC grew its position in Johnson & Johnson by 0.6% in the second quarter. Empirical Finance LLC now owns 85,653 shares of the company’s stock worth $13,083,000 after acquiring an additional 531 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. HSBC boosted their target price on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Finally, Stifel Nicolaus increased their price target on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $201.05.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $203.04 on Thursday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average price of $187.24 and a 200 day moving average price of $170.99. The company has a market cap of $489.18 billion, a price-to-earnings ratio of 19.60, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $203.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.